Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer

JAMA

Volumn 297, Issue 21, 2007, Pages 2410-2411

  Kangelaris, Kirsten N ^a   Gruber, Stephen B ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CELL INVASION; EDITORIAL; GASTRECTOMY; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; META ANALYSIS; MUTATION; PHENOTYPE; PRIORITY JOURNAL; STOMACH CANCER; FOUNDER EFFECT; GENETICS; HAPLOTYPE; NOTE; NUCLEOTIDE SEQUENCE; STOMACH TUMOR;

CADHERIN; CDH1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

CADHERINS; DNA MUTATIONAL ANALYSIS; FOUNDER EFFECT; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; MUTATION; STOMACH NEOPLASMS;

EID: 34249979864     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.21.2410     Document Type: Editorial

References (20)

1. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337-342.
2. Jones EG. Familial gastric cancer. N Z Med J. 1964;63:287-296.
3. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402-405.
4. Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg. 2006;202:612-617.
5. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344:1904-1909.
6. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130:612-619.
7. Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer. 2001;92:181-187.
8. Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4:262-275.
9. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360-2372.
10. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508-517.
11. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-1353.
12. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086-4089.
13. Guilford PJ, Hopkins JB, Grady WM, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14:249-255.
14. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873-880.
15. Oliveira S. Ferreira. Genetic screening for familial gastric cancer. Hereditary Cancer Clin Pract. 2004;2:51-64.
16. Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet. 2003;12:575-582.
17. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11:5401-5409.
18. Kim HC, Wheeler JM, Kim JC, et al. The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal cancer patients in Korea. Gut. 2000;47:262-267.
19. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-1388.
20. Canadian Cancer Society and National Cancer Institute of Canada. Canadian Cancer Statistics. Toronto, Ontario: Canadian Cancer Society and National Cancer Institute of Canada; 2007.